On November 19, 2026 Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, reported that the Canadian Intellectual Property Office (CIPO) has issued Patent Number 3,005,025 covering key aspects of Anixa’s ovarian cancer vaccine technology. The newly issued patent expands Anixa’s international intellectual property protection for a vaccine designed to harness the immune system to potentially prevent or treat ovarian cancer.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
The issued patent, exclusively licensed from Cleveland Clinic, is titled, "Ovarian Cancer Vaccines," and the co-inventors are Dr. Justin Johnson, the late Dr. Vincent Tuohy, both of Cleveland Clinic, and Dr. Suparna Mazumder, formerly of Cleveland Clinic. The patent covers methods of immunizing against the extracellular domain of anti-Müllerian hormone receptor II (AMHR2-ED), a protein domain expressed in normal ovaries prior to menopause and also aberrantly expressed in certain types of ovarian cancer.
Anixa’s ovarian cancer vaccine, being developed in collaboration with Cleveland Clinic, represents a novel approach to preventing and treating ovarian cancer, particularly among high-risk populations such as those carrying BRCA mutations or with a family history of the disease.
This "retired" protein strategy, developed at Cleveland Clinic and licensed exclusively to Anixa, is designed to train the immune system to recognize and target cells associated with ovarian cancer while seeking to avoid harm to normal tissue. The approach seeks to exploit differences in protein expression between normal tissues and cancer cells, potentially providing a new strategy for cancer treatment and prevention.
The ovarian cancer vaccine is part of Anixa’s broader cancer vaccine portfolio, which also includes its investigational breast cancer vaccine developed in collaboration with Cleveland Clinic. The breast cancer vaccine recently completed a Phase 1 clinical trial, funded by a grant from the U.S. Department of Defense, in which all primary endpoints were met. Anixa believes that targeting proteins associated with cancer may offer opportunities to develop preventive vaccines for multiple cancer types.
The Canadian patent issuance complements the Company’s existing patent protection in the United States. In July 2025, Anixa announced the issuance of U.S. Patent Number 12,357,593 covering key aspects of its ovarian cancer vaccine technology, including broad claims related to methods of eliciting an immune response targeting AMHR2-ED. Together, these patents provide protection in two important markets for Anixa’s approach to developing an ovarian cancer vaccine.
"This Canadian patent further strengthens the international patent protection around our ovarian cancer vaccine program and reinforces our intellectual property position in our AMHR2-ED-targeted immunoprevention approach," stated Dr. Amit Kumar, Chairman and CEO of Anixa Biosciences. "We believe vaccines designed to prevent cancer represent an important frontier in oncology. Our ovarian cancer vaccine is based on a differentiated scientific approach that targets a protein associated with ovarian cancer, with the long-term goal of preventing the disease before it develops. Strengthening our patent portfolio is an important part of our strategy to advance this technology and build a broader platform of cancer prevention vaccines."
(Press release, Anixa Biosciences, NOV 19, 2026, View Source [SID1234675007])